Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
David A. Bond, Ying Huang, Beth A. Christian, Samantha Jaglowski, Don Benson, Lapo Alinari, Robert A. Baiocchi, Jonathon B. Cohen, Kristie A. Blum & Kami J. Maddocks. (2022) A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma. Leukemia & Lymphoma 63:7, pages 1750-1753.
Read now
Read now
Ytel Garcilazo-Reyes, Maria-José Ibáñez-Juliá, Isaias Hernández-Verdin, Ludovic Nguyen-Them, Nadia Younan, Caroline Houillier, Khê Hoang-Xuan & Agusti Alentorn. (2020) Treating central nervous system lymphoma in the era of precision medicine. Expert Review of Precision Medicine and Drug Development 5:4, pages 275-281.
Read now
Read now
Yiqun Huang, Yong Zou, Luhui Lin, Xudong Ma & Ruiji Zheng. (2019) miR-101 regulates cell proliferation and apoptosis by targeting KDM1A in diffuse large B cell lymphoma. Cancer Management and Research 11, pages 2739-2746.
Read now
Read now
Wenli Cui, Shutao Zheng, Zebing Liu, Weige Wang, Ying Cai, Rui Bi, Bing Cao & Xiaoyan Zhou. (2017) PIK3CA expression in diffuse large B cell lymphoma tissue and the effect of its knockdown in vitro. OncoTargets and Therapy 10, pages 2239-2247.
Read now
Read now
Jorge J. Castillo, Zachary R. Hunter, Guang Yang & Steven P. Treon. (2017) Novel approaches to targeting MYD88 in Waldenström macroglobulinemia. Expert Review of Hematology 10:8, pages 739-744.
Read now
Read now
Cristian Massacesi, Emmanuelle Di Tomaso, Patrick Urban, Caroline Germa, Cornelia Quadt, Lucia Trandafir, Paola Aimone, Nathalie Fretault, Bharani Dharan, Ranjana Tavorath & Samit Hirawat. (2016) PI3K inhibitors as new cancer therapeutics: implications for clinical trial design. OncoTargets and Therapy 9, pages 203-210.
Read now
Read now
Xinlei Yu, Yun Chau Long & Han-Ming Shen. (2015) Differential regulatory functions of three classes of phosphatidylinositol and phosphoinositide 3-kinases in autophagy. Autophagy 11:10, pages 1711-1728.
Read now
Read now
Articles from other publishers (28)
Gaelen Shimkus & Taichiro Nonaka. (2023) Molecular classification and therapeutics in diffuse large B-cell lymphoma. Frontiers in Molecular Biosciences 10.
Crossref
Crossref
Gaelen Shimkus & Taichiro Nonaka. (2023) Molekulare Klassifizierung und Therapien des diffusen großzelligen B-Zell-Lymphoms. Kompass Onkologie 10:2, pages 59-76.
Crossref
Crossref
Yunying Zhu, Chenshuang Lei, Qian Jiang, Qinhua Yu & Liannv Qiu. (2022) DSF/Cu induces antitumor effect against diffuse large B-cell lymphoma through suppressing NF-κB/BCL6 pathways. Cancer Cell International 22:1.
Crossref
Crossref
Caitlin M. Stewart, Laure Michaud, Karissa Whiting, Reiko Nakajima, Chelsea Nichols, Stephanie De Frank, Paul A. HamlinJrJr, Matthew J. Matasar, John F. Gerecitano, Pamela Drullinsky, Audrey Hamilton, David Straus, Steven M. Horwitz, Anita Kumar, Craig H. Moskowitz, Alison Moskowitz, Andrew D. Zelenetz, Jurgen Rademaker, Gilles Salles, Venkatraman Seshan, Heiko Schöder, Anas Younes, Dana W.Y. Tsui & Connie Lee Batlevi. (2022) Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring. Clinical Cancer Research 28:1, pages 45-56.
Crossref
Crossref
Reza Shiri Heris, Atieh Pourbagheri-Sigaroodi, Amir-Mohammad Yousefi & Davood Bashash. (2021) The Superior Cytotoxicity of Dual Targeting of BCR/ABL and PI3K in K562 Cells: Proposing a Novel Therapeutic Potential for the Treatment of CML. Indian Journal of Hematology and Blood Transfusion 38:1, pages 51-60.
Crossref
Crossref
Waleska Kerllen Martins, Maryana do Nascimento da Silva, Kiran Pandey, Ikuko Maejima, Ercília Ramalho, Vania Claudia Olivon, Susana Nogueira Diniz & Daniel Grasso. (2021) Autophagy-targeted therapy to modulate age-related diseases: Success, pitfalls, and new directions. Current Research in Pharmacology and Drug Discovery 2, pages 100033.
Crossref
Crossref
Xiaowei Zhang & Yuanbo Liu. (2020) Targeting the PI3K/AKT/mTOR Signaling Pathway in Primary Central Nervous System Lymphoma: Current Status and Future Prospects. CNS & Neurological Disorders - Drug Targets 19:3, pages 165-173.
Crossref
Crossref
Feifei Sun, Xiaosheng Fang & Xin Wang. (2020) Signal Pathways and Therapeutic Prospects of Diffuse Large B Cell Lymphoma. Anti-Cancer Agents in Medicinal Chemistry 19:17, pages 2047-2059.
Crossref
Crossref
Mojgan Djavaheri-Mergny, Sylvie Giuriato, Mario P. Tschan & Magali Humbert. (2019) Therapeutic Modulation of Autophagy in Leukaemia and Lymphoma. Cells 8:2, pages 103.
Crossref
Crossref
Joanna Rhodes & Daniel J. Landsburg. (2018) Small-Molecule Inhibitors for the Treatment of Diffuse Large B Cell Lymphoma. Current Hematologic Malignancy Reports 13:5, pages 356-368.
Crossref
Crossref
Han Zhang. (2018) Targeting autophagy in lymphomas: a double-edged sword?. International Journal of Hematology 107:5, pages 502-512.
Crossref
Crossref
Anja Müller, Bernd Gillissen, Antje Richter, Anja Richter, Cindrilla Chumduri, Peter T. Daniel & Christian W. Scholz. (2018) Pan-class I PI3-kinase inhibitor BKM120 induces MEK1/2-dependent mitotic catastrophe in non-Hodgkin lymphoma leading to apoptosis or polyploidy determined by Bax/Bak and p53. Cell Death & Disease 9:3.
Crossref
Crossref
Chie Ishikawa, Masachika Senba & Naoki Mori. (2018) Effects of NVP‑BEZ235, a dual phosphatidylinositol�3-kinase/mammalian target of rapamycin inhibitor, on HTLV-1-infected T-cell lines. Oncology Letters.
Crossref
Crossref
Tabea ErdmannPavel KlenerJames T. LynchMichael GrauPetra VočkováJan MolinskyDiana TuskovaKevin HudsonUrszula M. PolanskaMichael GrondineMichele MayoBeiying DaiMatthias PfeiferKristian ErdmannDaniela SchwammbachMyroslav ZapukhlyakAnnette M. StaigerGerman OttWolfgang E. Berdel, Barry R. DaviesFrancisco CruzaleguiMarek TrnenyPeter Lenz, Simon T. BarryGeorg Lenz. (2017) Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL. Blood 130:3, pages 310-322.
Crossref
Crossref
Davood Bashash, Ava Safaroghli-Azar, Mahda Delshad, Samaneh Bayati, Elaheh Nooshinfar & Seyed H. Ghaffari. (2016) Inhibitor of pan class-I PI3K induces differentially apoptotic pathways in acute leukemia cells: Shedding new light on NVP-BKM120 mechanism of action. The International Journal of Biochemistry & Cell Biology 79, pages 308-317.
Crossref
Crossref
Michael T. Tees & Lubomir Sokol. (2016) Novel Pharmacotherapies for B-Cell Lymphomas and Leukemias. American Journal of Therapeutics 23:2, pages e498-e520.
Crossref
Crossref
Kai Xue, Juan J. Gu, Qunling Zhang, Cory Mavis, Francisco J. Hernandez-Ilizaliturri, Myron S. Czuczman & Ye Guo. (2015) Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents. Journal of Cancer Research and Clinical Oncology 142:2, pages 379-387.
Crossref
Crossref
Charles B Goodwin & Rebecca J. Chan. 2016. PI3K-mTOR in Cancer and Cancer Therapy. PI3K-mTOR in Cancer and Cancer Therapy
181
229
.
Matteo Allegretti, Maria Rosaria Ricciardi, Roberto Licchetta, Simone Mirabilii, Stefania Orecchioni, Francesca Reggiani, Giovanna Talarico, Roberto Foà, Francesco Bertolini, Sergio Amadori, Maria Rosaria Torrisi & Agostino Tafuri. (2015) The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia. Scientific Reports 5:1.
Crossref
Crossref
Rosalba Camicia, Hans C. Winkler & Paul O. Hassa. (2015) Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. Molecular Cancer 14:1.
Crossref
Crossref
João Kleber Novais Pereira, João Agostinho Machado-Neto, Matheus Rodrigues Lopes, Beatriz Corey Morini, Fabiola Traina, Fernando Ferreira Costa, Sara Teresinha Olalla Saad & Patricia Favaro. (2015) Molecular effects of the phosphatidylinositol-3-kinase inhibitor NVP-BKM120 on T and B-cell acute lymphoblastic leukaemia. European Journal of Cancer 51:14, pages 2076-2085.
Crossref
Crossref
Ilyas Sahin, Feda Azab, Yuji Mishima, Michele Moschetta, Brian Tsang, Siobhan V. Glavey, Salomon Manier, Yu Zhang, Antonio Sacco, Aldo M. Roccaro, Abdel Kareem Azab & Irene M. Ghobrial. (2014) Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib. American Journal of Hematology 89:11, pages 1030-1036.
Crossref
Crossref
Agata Majchrzak, Magdalena Witkowska & Piotr Smolewski. (2014) Inhibition of the PI3K/Akt/mTOR Signaling Pathway in Diffuse Large B-Cell Lymphoma: Current Knowledge and Clinical Significance. Molecules 19:9, pages 14304-14315.
Crossref
Crossref
Alok R. Singh, Susan K. Peirce, Shweta Joshi & Donald L. Durden. (2014) PTEN and PI-3 kinase inhibitors control LPS signaling and the lymphoproliferative response in the CD19+ B cell compartment. Experimental Cell Research 327:1, pages 78-90.
Crossref
Crossref
Laia Rosich, Arnau Montraveta, Sílvia Xargay-Torrent, Mónica López-Guerra, Jocabed Roldán, Marta Aymerich, Itziar Salaverria, Sílvia Beà, Elías Campo, Patricia Pérez-Galán, Gaël Roué & Dolors Colomer. (2014) Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma. Oncotarget 5:16, pages 6788-6800.
Crossref
Crossref
Alba Matas-Céspedes, Vanina Rodriguez, Susana G. Kalko, Anna Vidal-Crespo, Laia Rosich, Teresa Casserras, Patricia Balsas, Neus Villamor, Eva Giné, Elías Campo, Gaël Roué, Armando López-Guillermo, Dolors Colomer & Patricia Pérez-Galán. (2014) Disruption of Follicular Dendritic Cells–Follicular Lymphoma Cross-talk by the Pan-PI3K Inhibitor BKM120 (Buparlisib). Clinical Cancer Research 20:13, pages 3458-3471.
Crossref
Crossref
A Lonetti, I L Antunes, F Chiarini, E Orsini, F Buontempo, F Ricci, P L Tazzari, P Pagliaro, F Melchionda, A Pession, A Bertaina, F Locatelli, J A McCubrey, J T Barata & A M Martelli. (2013) Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia. Leukemia 28:6, pages 1196-1206.
Crossref
Crossref
Xiaosheng Fang, Xiangxiang Zhou & Xin Wang. (2013) Clinical development of phosphatidylinositol 3-kinase inhibitors for non-Hodgkin lymphoma. Biomarker Research 1:1.
Crossref
Crossref